Bavarian Nordic Wins Swiss Approval for Chikungunya Vaccine

COPENHAGEN, Denmark, April 16, 2026

Bavarian Nordic A/S has announced that Swissmedic, the Swiss Agency for Therapeutic Products, has granted approval for its VIMKUNYA® chikungunya vaccine (recombinant, adsorbed) for active immunization in individuals aged 12 years and older. This milestone marks the first approval of a chikungunya vaccine in Switzerland, reinforcing the company’s leadership in infectious disease prevention and expanding global access to innovative vaccines targeting emerging viral threats.

Regulatory Milestone Expands Global Vaccine Access

The Swissmedic approval represents the fourth regulatory authorization for VIMKUNYA, following earlier approvals by the U.S. Food and Drug Administration (FDA), the European Commission, and the UK Medicines and Healthcare products Regulatory Agency (MHRA) in 2025. The Swiss decision was based on a comprehensive regulatory submission filed in July 2025, supported by clinical and immunogenicity data demonstrating the vaccine’s safety and efficacy.

This latest approval underscores Bavarian Nordic’s strategic commitment to expanding global access to vaccines for emerging infectious diseases, particularly those with increasing geographic spread. The company has also submitted an application to Health Canada, with a potential decision expected in the first half of 2026, further strengthening its international regulatory footprint.

Leadership at Bavarian Nordic emphasized that the Swiss approval is a key step in delivering protection against chikungunya to broader populations, especially in regions at risk of outbreaks. The growing list of approvals highlights strong regulatory confidence in the vaccine’s clinical profile and public health value.

Innovative VLP Vaccine Technology and Clinical Benefits

VIMKUNYA is a single-dose, prefilled, adjuvanted virus-like particle (VLP) recombinant protein vaccine, designed to provide rapid and robust immune protection against chikungunya virus (CHIKV). The vaccine induces a strong seroresponse, with protective immunity developing as early as one week after administration, making it particularly valuable in outbreak settings and travel-related exposures.

Unlike traditional vaccines, VIMKUNYA does not contain viral genetic material, making it non-infectious and incapable of causing disease. This feature enhances its safety profile and allows for broader use across diverse populations. The convenience of a single-dose regimen combined with rapid onset of immunity positions the vaccine as a highly effective tool in preventing chikungunya infections.

The use of advanced VLP technology reflects a growing trend in vaccine development, where structural mimicry of viruses enables strong immune responses without the risks associated with live or attenuated pathogens. This innovation is expected to play a significant role in combating emerging viral diseases globally.

Addressing a Growing Global Health Threat

Chikungunya is a mosquito-borne viral disease that has rapidly expanded across Asia, Africa, Europe, and the Americas, with increasing incidence over the past two decades. The disease is characterized by fever, rash, fatigue, and severe joint pain, which can become chronic in 30–40% of patients, lasting months or even years.

Recent global data indicate that more than 500,000 cases and nearly 200 deaths were reported in 2025, highlighting the urgent need for preventive measures. In Europe alone, over 1,000 locally transmitted cases were recorded, reflecting the virus’s expanding geographic reach.

The approval of VIMKUNYA provides a critical preventive solution in the absence of widely available vaccines, addressing a major gap in public health preparedness. The vaccine’s ability to deliver early and sustained immunity is particularly important in mitigating the impact of unpredictable outbreaks and protecting vulnerable populations, including travelers and residents in endemic regions.

With chikungunya continuing to spread globally and often being underdiagnosed due to similarities with other viral infections such as dengue, the availability of an effective vaccine marks a significant advancement in infectious disease control. Bavarian Nordic’s expanding regulatory success positions VIMKUNYA as a key component in global strategies aimed at reducing the burden of mosquito-borne diseases.

As the company continues to pursue additional approvals and scale access worldwide, VIMKUNYA stands out as a breakthrough innovation that could significantly reduce the health and economic impact of chikungunya outbreaks.

Source: Bavarian Nordic press release